A Study to Evaluate Oxygen Supplementation Duration to Assess Resolution of Acute Hypoxic Respiratory Failure

Overview

About this study

The purpose of this study is to assess the feasibility, reliability and validity of oxygen supplementation duration as an intermediate outcome of resolution of acute hypoxic respiratory failure from all cause in comparison with PaO2/FiO2, SaO2/FiO2 ratio, and lung injury score trajectories in critically ill patients with acute respiratory failure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • All ICU admissions with onset of acute hypoxemic respiratory failure within 24 hours of admission including transfer from the general hospital floor.
  • Acute hypoxemic respiratory failure will be defined as one of the following:
    • PaO2 < 60mm/Hg or SpO2 < 91% on 0.2 FiO2;
    • P/F < 2300;
    • PaO2 decrease y 10 mm/Hg from known baseline. 
  • Readmission within 24 hours of discharge will be included in the initial admission.

Exclusion Criteria:

  • Patients with comfort measures placed within 24 hours of ICU admission.
  • Patients with hyperventilation as the cause of their hypoxemia.
  • Timing of onset of respiratory failure cannot be obtained (possibly associated with transfer from outlying facility).
  • Patients with chronic hypoxic respiratory failure prior to adission.
  • Patient study consent could not be verified.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ognjen Gajic, M.D.

Contact us for the latest status

Contact information:

Ognjen Gajic M.D.

(507)284-2416

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20476330

Mayo Clinic Footer